Founded in 2022, Mosanna Therapeutics is a clinical-stage biotech company pioneering a novel pharmaceutical approach to treating obstructive sleep apnea (OSA) with an easily administered nasal spray. Designed to help restore the body's natural airway control during sleep, Mosanna's lead therapy, MOS118, offers a drug-based alternative to traditional mechanical treatments and is currently being evaluated in a Phase 1 clinical trial.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/09/25 | $80,000,000 | Series A |
Broadview Ventures EQT Life Sciences Forbion Capital Partners Forty51 Ventures High-Tech Gruenderfonds Norwest Venture Partners Pivotal bioVenture Partners  Supermoon Capital | undisclosed |
